AMCo revenue much stronger than expected with Fx headwindsTheir US revenue was lower than expected with a full quarter impact of generic competition for Dibenzyline. It looks like they've expanded their sales force towards the end of 2015 and into 2016 with respect to Donnatal (see MD&A p13) so I would expect Q1 to show some growth in the US.
However, their International (AMCo) Revenue was over $20 million higher than expected. This is quite suprising considering the GBP/US$ Fx headwinds for the quarter. International is now the larger and faster growing segment of their business ("mid-teen growth"). I guess I shouldn't have been surprised looking at the very strong upward trend in UK quarterly sales as shown on p.10 of their Winter 2016 Presentation.
Should see some even better cash flow in Q1 as they get a full quarter out of AMCo.